Related Experiment Video
Updated: Aug 9, 2026

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients
Published on: April 3, 2026
The rationale for using apoA-I as a clinical marker of cardiovascular risk
1The Heart Research Institute, Sydney, Australia. barterp@hri.org.au
Insights
High-density lipoprotein (HDL) cholesterol is linked to lower cardiovascular risk. Measuring apolipoprotein A-I (apoA-I) may improve cardiovascular risk assessment.
Area of Science:
- Cardiovascular Science
- Lipid Metabolism
- Biochemistry
Background:
- Established inverse relationship between high-density lipoprotein (HDL) cholesterol and cardiovascular disease (CVD) risk.
- HDLs possess protective functions, including cholesterol efflux from macrophages and anti-inflammatory/antioxidant properties.
Purpose of the Study:
- To highlight the significance of apolipoprotein A-I (apoA-I) in HDL's protective functions.
- To advocate for the inclusion of apoA-I measurement in cardiovascular risk assessment.
Main Methods:
- Review of documented functions of HDLs and their primary apolipoprotein, apoA-I.
- Analysis of apoA-I's role in cholesterol efflux and anti-inflammatory/antioxidant processes.
Main Results:
- ApoA-I is central to HDL's cholesterol-removing and anti-inflammatory capabilities.
- These functions collectively contribute to HDL's cardioprotective effects.
Conclusions:
- ApoA-I's pivotal role in HDL function supports its clinical relevance.
- Measuring apoA-I could enhance the accuracy of human cardiovascular risk stratification.
Abstract:
An inverse relationship between the concentration of high-density lipoprotein (HDL) cholesterol and the risk of developing cardiovascular is well established. There are several documented functions of HDLs that may contribute to a protective role of these lipoproteins. These include the ability of HDLs to promote the efflux of cholesterol from macrophages and foam cells in the artery wall and to anti-inflammatory/antioxidant properties of these lipoproteins. The fact that the main apolipoprotein of HDLs, apoA-I, plays a prominent role in each of these functions adds support to the view that apoA-I should be measured as a component of the assessment of cardiovascular risk in humans.
Related Concept Videos
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease I: Introduction
Atherosclerosis I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations